Institutional Investor’s Pro-Recro Pharma (NASDAQ:REPH) Sentiment In 2018 Q1

August 19, 2018 - By Billy Entrekin

Recro Pharma, Inc. (NASDAQ:REPH) Logo

Sentiment for Recro Pharma (NASDAQ:REPH)

Recro Pharma (NASDAQ:REPH) institutional sentiment increased to 2.37 in Q1 2018. Its up 0.87, from 1.5 in 2017Q4. The ratio has increased, as 45 hedge funds opened new and increased equity positions, while 19 reduced and sold stock positions in Recro Pharma. The hedge funds in our partner’s database reported: 10.95 million shares, up from 9.57 million shares in 2017Q4. Also, the number of hedge funds holding Recro Pharma in their top 10 equity positions increased from 0 to 2 for an increase of 2. Sold All: 5 Reduced: 14 Increased: 22 New Position: 23.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company has market cap of $126.80 million. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. It currently has negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

The stock increased 5.15% or $0.3 during the last trading session, reaching $6.12. About 70,587 shares traded. Recro Pharma, Inc. (NASDAQ:REPH) has declined 32.73% since August 19, 2017 and is downtrending. It has underperformed by 45.30% the S&P500.

Analysts await Recro Pharma, Inc. (NASDAQ:REPH) to report earnings on November, 8. They expect $-0.75 EPS, down 56.25 % or $0.27 from last year’s $-0.48 per share. After $-0.62 actual EPS reported by Recro Pharma, Inc. for the previous quarter, Wall Street now forecasts 20.97 % negative EPS growth.

Broadfin Capital Llc holds 3.84% of its portfolio in Recro Pharma, Inc. for 2.24 million shares. Lyon Street Capital Llc owns 1.03 million shares or 3.64% of their US portfolio. Moreover, Sphera Funds Management Ltd. has 0.61% invested in the company for 364,197 shares. The New York-based Opus Point Partners Management Llc has invested 0.27% in the stock. Kingdon Capital Management L.L.C., a New York-based fund reported 260,352 shares.

Since January 1, 0001, it had 0 insider buys, and 3 sales for $3.19 million activity.

Recro Pharma, Inc. (NASDAQ:REPH) Ratings Coverage

Ratings analysis reveals 100% of Recro Pharma’s analysts are positive. Out of 4 Wall Street analysts rating Recro Pharma, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $1100 while the high is $21.2500. The stock’s average target of $15.81 is 158.33% above today’s ($6.12) share price. REPH was included in 4 notes of analysts from February 28, 2018. The rating was maintained by Piper Jaffray on Wednesday, February 28 with “Buy”. The rating was initiated by Berenberg on Thursday, April 19 with “Buy”. On Thursday, May 10 the stock rating was maintained by Oppenheimer with “Buy”.

More notable recent Recro Pharma, Inc. (NASDAQ:REPH) news were published by: Globenewswire.com which released: “SHAREHOLDER ALERT: ATEN ANW DB QCOM FPI FIZZ SBGL ACAD FLR REPH: The Law Offices of Vincent Wong …” on July 24, 2018, also Globenewswire.com with their article: “CLASS ACTION UPDATE for FIZZ, ACAD and REPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on …” published on July 25, 2018, Globenewswire.com published: “CLASS ACTION UPDATE for QCOM, FLR, FPI and REPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions …” on July 24, 2018. More interesting news about Recro Pharma, Inc. (NASDAQ:REPH) were released by: Globenewswire.com and their article: “CLASS ACTION UPDATE for ATEN, FLR and REPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on …” published on July 23, 2018 as well as Seekingalpha.com‘s news article titled: “Recro Pharma, Inc. (REPH) CEO Geraldine Henwood on Q2 2018 Results – Earnings Call Transcript” with publication date: August 07, 2018.

Recro Pharma, Inc. (NASDAQ:REPH) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.